Pharmacologic Substance – Page 192

“#FierceMadness 2024: Best Biotech Name Tournament Round of 32 Results”

2 years ago talkbio0Tagged Beyfortus, biotech, Biotech Name, Daybue, drug names, Fierce, FierceMadness, Marketing Suitability, Mounjaro, results, Round shape, Tournament, Wainua

#FierceMadness, Best Biotech Name Tournament, Round of 32 Results, Drug Names, Marketing Suitability, Mounjaro, Daybue, Beyfortus, Wainua, Fierce Biotech, Voting Results

Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment

2 years ago talkbio0Tagged Anemia, Sickle Cell, ClinicalTrials.gov, Grail, inclacumab, Pfizer, Phase 3 Clinical Trials, Poor Accrual, Recruitment Challenges, THRIVE Program

Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies

AstraZeneca’s Ultomiris Gains FDA Approval for Rare Autoimmune Condition – NMOSD

2 years ago talkbio0Tagged Approved, AstraZeneca, Autoimmune Diseases, dosing, Infrequent, Long-acting C5 complement inhibitor, Neuromyelitis Optica, Rating (action), ravulizumab-cwvz, Reduced, Relapse, Ultomiris, United States Food and Drug Administration, With frequency

AstraZeneca, Ultomiris, ravulizumab-cwvz, FDA Approval, Rare Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), Long-acting C5 complement inhibitor, Phase 3 CHAMPION-NMOSD Trial, Reduced Relapse Rate, Dosing Frequency

Axsome Therapeutics’ Small Molecule AXS-12 Successful in Phase III Narcolepsy Trial

2 years ago talkbio0Tagged AXS-12, Axsome, Cataplexy, Drowsiness, Improved, memory/, Narcolepsy, Phase 3 Clinical Trials, reboxetine, safety profile, Severities

Axsome Therapeutics, AXS-12 (reboxetine), Phase III trial, Narcolepsy, Cataplexy reduction, Improved cognition/ memory/ sleepiness severity, Safety profile

Alexion Expands Indications for Long-Acting C5 Complement Inhibitor Ultomiris in Rare Autoimmune Disorder NMOSD

2 years ago talkbio0Tagged Alexion, Annals, Approved, AstraZeneca Rare Disease, C5 complement inhibitor, CHAMPIER-NMOSD trial, generalised myasthenia gravis, gMG, long-acting, Marc Dunoyer, Neurology speciality, Neuromyelitis Optica, Paroxysmal nocturnal hemoglobinuria, Publications, ravulizumab-cwvz, Ultomiris, United States Food and Drug Administration

Ultomiris, ravulizumab-cwvz, C5 complement inhibitor, neuromyelitis optica spectrum disorder (NMOSD), FDA approval, long-acting, zero relapses, CHAMPIER-NMOSD trial, Annals of Neurology publication, Marc Dunoyer, AstraZeneca Rare Disease, Alexion, generalised myasthenia gravis (gMG), paroxysmal nocturnal haemoglobinuria (PNH).

AbbVie Acquires Landos Biopharma to Enhance Post-Humira Immunology Pipeline

2 years ago talkbio0Tagged AbbVie, autoimmune startup, Humira, Immunology pipeline, Inflammatory Bowel Diseases, Landos Biopharma, Small acquisition

AbbVie, Landos Biopharma, Small acquisition, IBD (Inflammatory Bowel Disease) drug, Humira, Autoimmune startup, Immunology pipeline

Novo Nordisk Acquires Mid-Stage Heart Failure Biotech Cardior for Up to $1.1 Billion

2 years ago talkbio0Tagged Acquisition (action), biotech, Cardior, Heart failure, Nordisk

Novo Nordisk, Cardior Pharmaceuticals, Heart Failure Biotech, Acquisition, $1.1 billion

Roche’s Phase III Trial Success with IL-6 Blocker Enspryng Tempered by Modest Outcomes

2 years ago talkbio0Tagged Blocker, disappointment, Enspryng, Expectations, interleukin-6, Myasthenia Gravis, Generalized, Phase 3 Clinical Trials, Roche (company), satralizumab

Roche, IL-6 blocker, Enspryng (satralizumab), Phase III trial, Generalized Myasthenia Gravis (gMG), Disappointment, Expectations

Medicare Partially Covers Weight Loss Drugs Amidst High Price Concerns and Future Negotiation Prospects

2 years ago talkbio0Tagged accessibility, Administration occupational activities, Affordability, Increased, Mediation, Medicare, Obesity drugs, premium, Prices, semaglutide, utilization qualifier, Wegovy

Medicare, Obesity drugs, Wegovy, Semaglutide, Price negotiation, Affordability, Accessibility, Premium increases, Utilization management

EU Approves Novo Nordisk’s Groundbreaking Once-Weekly Basal Insulin Icodec for Adults with Diabetes

2 years ago talkbio0Tagged Awiqli, CHMP, European Medicines Agency, insulin icodec, Nordisk, Once-Weekly Insulin Shot

Novo Nordisk, Once-Weekly Insulin Shot, Awiqli, Insulin Icodec, European Medicines Agency (EMA), CHMP Positive Opinion, Type 1 & Type 2 Diabetes Treatment